会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 10. 发明授权
    • Thia-and oxazoles and their use as ppars activators
    • Thia和恶唑及其作为ppars激活剂的用途
    • US07196107B2
    • 2007-03-27
    • US10451307
    • 2001-12-18
    • Paul John BeswickVipulkumar PatelMichael Lawrence Sierra
    • Paul John BeswickVipulkumar PatelMichael Lawrence Sierra
    • A61K31/426A61K31/421C07D277/20C07D263/30
    • C07D277/24
    • A compound of formula (I) or pharmaceutically acceptable salts and solvates thereof. R1 and R2 are independently H or C1-3alkyl, m is 0–3; X1 is NH, NCH3, O, S; R3, R4 and R5 are independently H, CH3, CF3, OCH3, allyl or halogen; X2 is (CR10R11)n wherein n is 1 or 2; R10 and R11 independently represent H, fluorine or C1-16alkyl; R26 and R27 are independently H, C1-3 alkyl or R26 and R27 together with the carbon atom to which they are bonded form a 3–5 membered cycloalklyl ring. R6 and R7 independently represent H, fluorine or C1-16alkyl; R9 is C1-6alkyl or CF3; One of Y and Z is N, the other is S or O; Each R8 independently represents CF3, OCH3, CH3 or halogen; y is O, 1, 2, 3, 4, 5. Use of a compound of formula (I) for the manufacture of a medicament for the prevention or treatment of a hPPAR mediated disease or condition, such as dyslipidemia, syndrome X, heart failure, hypercholesteremia, cardiovascular disease, type II diabetes mellitus, type 1 diabetes, insulin resistance hyperlipidemia, obesity, anorexia bulimia, inflammation and anorexia nervosa
    • 式(I)化合物或其药学上可接受的盐和溶剂化物。 R 1和R 2独立地为H或C 1-3烷基,m为0-3; X 1是NH,NCH 3,O,S; R 3,R 4和R 5独立地为H,CH 3,CF 3, OCH 3,OCH 3,烯丙基或卤素; 其中n为1或2;(3)其中n为1或2; R 10和R 11独立地代表H,氟或C 1-16烷基; R 26和R 27独立地是H,C 1-3烷基或R 26和R 26, 27与它们所键合的碳原子一起形成3-5元环烯基环。 R 6和R 7独立地表示H,氟或C 1-16烷基; R 9是C 1-6烷基或CF 3 N; Y和Z之一是N,另一个是S或O; 每个R 8独立地表示CF 3,OCH 3,CH 3或卤素; y是O,1,2,3,4,5。式(I)化合物在制备用于预防或治疗hPPAR介导的疾病或病症如血脂异常,综合征X,心脏的药物中的用途 失败,高胆固醇血症,心血管疾病,II型糖尿病,1型糖尿病,胰岛素抵抗性高脂血症,肥胖,厌食症,炎症和神经性厌食